Heart Failure with Reduced Ejection Fraction (HFrEF) | Drugs Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

331,928 results for “Heart Failure with Reduced Ejection Fraction (HFrEF)”

Investigational

Tovinontrine

Manufacturer: Cardurion Pharmaceuticals

Conditions: Heart failure with reduced ejection fraction (HFrEF), Heart failure with preserved ejection fraction (HFpEF)

C₂₁H₂₆N₆O₂

heart regeneration therapy (congestive heart failure)

Heart Failure(River Biomedics)

nanoparticle therapeutics (heart failure)

RXFP1 agonist (heart failure)

mNCE inhibitor (heart failure)

CVie-216

stem cell therapies (heart failure)

GDF15 modulator (congestive heart failure)

iPSC-derived cardiomyocytes (heart failure)

Page 1 of 186